Published: 2021-08-18 12:43 | Updated: 2021-08-19 10:24

BioNut researcher receives EFSD / Novo Nordisk Future Leaders Award

Rongrong Fan, Department of Biosciences and Nutrition.

Assistant Professor Rongrong Fan at the Department of Biosciences and Nutrition is among the 4 grantees in Europe who have received 5 million DKK for 5 years from the EFSD / Novo Nordisk Future Leaders Award program in 2021. This highly competitive grant supports young and promising researchers of excellence who wish to further develop their career in Europe to investigate the mechanisms of diabetes.

From epigenetics to functional epigenetics: investigating enhancers and silencers in human metabolic tissues

Rongrong Fan, Department of Biosciences and Nutrition, received the grant for the project: "From epigenetics to functional epigenetics: investigating enhancers and silencers in human metabolic tissues"

Type 2 diabetes is accounting for 90% of all diabetic cases and is becoming global pandemic.

Rongrong Fan’s research focuses on the transcriptional regulation of metabolism and inflammation in the major metabolic organs (such as adipose tissue, liver) and immune cells. The latest finding by the team revealed dual roles of non-coding genomic regions and their interplay with local transcription factors and cofactors in controlling gene expression1. Disturbance of such process, i.e. by mutations in the genome, leads to the metabolic dysregulations and is linked with obesity-induced insulin resistance1-3.

"By developing novel functional screening techniques, we are now able to systemically study the molecular features and regulatory mechanisms of those regions in human metabolic tissues genome-widely", says Rongrong Fan. 

"We hope to substantially increase our knowledge in the functional genomic basis of the disease. Such information is critical for developing personalized therapeutic strategies which will ultimately benefit the patients".

References

1. Huang, Z., et al. The corepressors GPS2 and SMRT control enhancer and silencer remodeling via eRNA transcription during inflammatory activation of macrophages. Molecular Cell 2021. 81(5):953-968.

2. Liang, N., et al. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα. Nature Communications 2019. 10:1684.

3. Fan, R.R., et al.  Loss of the corepressor GPS2 sensitizes macrophage activation upon metabolic stress induced by obesity and type 2 diabetes. Nature Medicine 2016. 22(7):780-91.

Contact

Event type
Lectures and seminars
Webinar: Writing a successful ERC Starting or Consolidator grant proposal (Part 2)

17-09-2021 9:30 am - 11:30 am Add to iCal
Online
Lead

Are you planning to apply to the ERC Starting Grant or Consolidator Grant 2022 calls with KI as host? If so, Grants Office invites you to an online workshop entitled ‘Writing a successful ERC grant proposal’.

Content

The workshop will be led by Dr. Mette Skraastad from Yellow Research, a consultant with extensive experience in supporting ERC applications. The focus will be on how to develop a competitive proposal considering panel specifics and type of project, and how to interpret and address the evaluation criteria. For more information, please see the attached leaflet.

The workshop will consist of two webinars on consecutive days. Attendance is free of charge, but registration is required and registered participants are expected to attend both sessions. Please note that you will also be expected to do a small amount of preparation ahead of the event.

Webinar times:

16th September 2021 09:30 - 11:30 (part 1)

17th September 2021 09:30 - 11:30 (part 2)

To register, please e-mail grantsoffice@ki.se

Contact

Event type
Lectures and seminars
Webinar: Writing a Successful ERC Starting or Consolidator Grant Proposal (Part 1)

16-09-2021 9:30 am - 11:30 am Add to iCal
Online
Lead

Are you planning to apply to the ERC Starting Grant or Consolidator Grant 2022 calls with KI as host? If so, Grants Office invites you to an online workshop entitled ‘Writing a successful ERC grant proposal’.

Content

The workshop will be led by Dr. Mette Skraastad from Yellow Research, a consultant with extensive experience in supporting ERC applications. The focus will be on how to develop a competitive proposal considering panel specifics and type of project, and how to interpret and address the evaluation criteria. For more information, please see the attached leaflet.

The workshop will consist of two webinars on consecutive days. Attendance is free of charge, but registration is required and registered participants are expected to attend both sessions. Please note that you will also be expected to do a small amount of preparation ahead of the event.

Webinar times:

16th September 2021 09:30 - 11:30 (part 1)

17th September 2021 09:30 - 11:30 (part 2)

To register, please e-mail grantsoffice@ki.se

Contact

Published: 2021-08-17 11:41 | Updated: 2021-08-17 11:59

BioNut researchers receive grants from Cancer Research KI

Collaboration global network
Photo: kadirkaba GettyImages

Congratulations to Marco Gerling, Andreas Lennartsson and Staffan Strömblad at the Department of Biosciences and Nutrition (BioNut), who have received the Translational Seed Funding grant / Blue Sky Research grant from Cancer Research KI.

The Translational Seed Funding grant is supporting collaboration between two scientists in the fields of Basic cancer research and clinical cancer research. It is awarded for two years with amounts to SEK 750 000 + 25 % INDI per year. We wish to congratulate:

  • Marco Gerling, BioNut, who together with Ernesto Sparrelid at CLINTEC, was awarded the grant for a project on "Single cell studies of metastasis invasion in pancreatic cancer".
  • Andreas Lennartsson, BioNut, who together with Martin Jädersten at MedH, was awarded the grant for a project on "Identification of novel therapeutic targets disrupting the cell interactions between AML and stroma in the bone marrow niche".

The Blue Sky Research grant for Innovative Cancer Research is a one-year grant, providing SEK 500 000, to support an innovative, "high risk and high reward" pilot project aimed at demonstrating proof of principle. We wish to congratulate:

  • Staffan Strömblad, BioNut, who was awarded the grant for a project on "How may Mechanotransduction Prevent Cancer?"

 

Published: 2021-07-07 08:35 | Updated: 2021-08-25 17:44

KI researcher receives 38 million SEK for research on Parkinson's disease

Per Svenningsson vid KI får 38 miljoner kronor från Nordstjernan Holding AB och Axel Johnson Gruppen. Foto: Stefan Zimmerman

Professor Per Svenningsson at Karolinska Institutet receives funding for a five-year research project of 38 million SEK from Nordstjernan Holding AB and the Axel Johnson Group. The investment goes to fundamental research on the onset of Parkinson's disease and to clinical studies to improve treatment and slow down the course of the disease.

Dr Xiaoqun Zhang, Antonia Ax:son Johnson from Axel Johnson Group, Göran Ennerfelt from Nordstjernan Holding AB and Per Svenningsson at KI. Photo: Stefan Zimmerman

"We are very pleased to be able to concretely contribute to the research at Karolinska Institutet that focuses on increasing the understanding and treatment of Parkinson's disease", says Göran Ennerfelt, Axel Johnson Group.

"We are pleased to contribute to this investment in developing drugs for a serious disease and reduce the suffering that affects many people around the world", says Kurt Almqvist, Nordstjernan Holding AB.

"The funds enable a pioneering and long-term investment in research on Parkinson's disease at Karolinska Institutet. In addition, the initiative stimulates younger researchers to work in the field, not least by offering opportunities for international collaborations including Harvard Medical School," says Per Svenningsson at the Department of Clinical Neuroscience.

Parkinson's disease is a neurological disease that more than 6 million people in the world suffer from. The diagnosis is based on clinical examination and the presence of stiffness, slowness and tremors, but many patients also suffer from non-motor symptoms. Decreased levels of the neurotransmitter dopamine cause many of the symptoms and can initially be treated with drugs that replace the lost dopamine.

Research on slowing down progression of Parkinson's disease

The next breakthrough in the treatment of Parkinson's disease is a therapy that slows down disease progression. A neuropathological feature of Parkinson's disease is α-synuclein-containing protein aggregates called Lewy bodies. These spread in the brain of people with Parkinson's disease as the disease progresses. Within the framework of this research program, the origin and distribution of Lewy bodies will be studied to identify possible targets for disease modifying therapies.

Published: 2021-07-06 15:32 | Updated: 2021-07-06 15:33

Seven researchers at NVS receive grants from The Swedish Brain Foundation 2021

Photo of woman blowing confetti.
Photo: iStock

This year, The Swedish Brain Foundation will distribute SEK 106 million in research grants. Karolinska Institutet is awarded 42% of these and includes seven researchers at the Department of Neurobiology, Health Sciences and Society (NVS) as recipients.

Maria Eriksdotter, Division of Clinical Geriatrics
Fortsatta studier av NGF, BDNF och modulatorer som terapi vid Alzheimers sjukdom

Daniel Ferreira, Division of Clinical Geriatrics
‘FindDLB’ – A leading platform for Swedish research in Dementia with Lewy Bodies

Per Nilsson, Division of Neurogeriatrics
Autofagi som potentiell terapi för Alzheimers tau patologi

Marianne Schultzberg, Division of Neurogeriatrics
Pro-resolverande behandling i Alzheimers sjukdom – inflammationens goda sida

Lars Tjernberg, Division of Neurogeriatrics
Patogena mekanismer i nervceller - Nanoskopi ger ledtrådar till behandling av AD

Eric Westman, Division of Clinical Geriatrics
Precisionsmedcin, svaret till gåtan Alzheimers sjukdom?

Bengt Winblad, Division of Neurogeriatrics
Utveckling av nya modulatorer av FKBP51 för behandling av Alzheimer sjukdom

 

Published: 2021-06-28 12:54 | Updated: 2021-06-28 12:54

Marie Skłodowska-Curie Innovative Training Network grant of 250,000 EUR to Roman Zubarev

Roman Zubarev leaning towards his desk.

Roman Zubarev has been funded within the Marie Skłodowska-Curie action “Innovative Training Networks”. The project aims to train a new generation of scientists in exploiting the concept of allostery in drug design.

The EU project ALLODD (allostery of drug design) will be coordinated from Athens, Greece. Karolinska Institutet is one of 12 organizations within the project. The total budget is 3.2 million EUR for 36 months.

The network aims to train a new generation of scientists in exploiting the concept of allostery in drug design. By putting together a whole array of technologies it aims to identify and characterize allosteric modulators of protein function that will be applied to therapeutically relevant systems.

“KI’s role will be to develop and share with other network participants novel methods of protein structural analysis by hydrogen-deuterium exchange mass spectrometry and chemical proteomics. These efforts will also be useful for SciLifeLab, where our Chemical proteomics facility is well appreciated”, says Roman Zubarev, Professor at the Department of Medical Biochemistry and Biophysics.

Marie Skłodowska-Curie action “Innovative Training Networks”

ITNs support competitively selected joint research training and/or doctoral programmes, implemented by European partnerships of universities, research institutions, and non-academic organisations.

The research training programmes provide experience outside academia, hence developing innovation and employability skills. ITNs include industrial doctorates, in which non-academic organisations have an equal role to universities in respect of the researcher's time and supervision, and joint doctoral degrees delivered by several universities. Furthermore, non-European organisations can participate as additional partners in ITNs, enabling doctoral-level candidates to gain experience outside Europe during their training.

Contact

Published: 2021-06-28 12:32 | Updated: 2021-06-28 12:44

CIMED grants 2022-2024 at BioNut

Congratulations to the researchers at BioNut who received funding from CIMED for 2022-2024. A total of 4.5 million SEK awarded.

CIMED project grant 2022-2024 - Senior

Anna Rising

A new injectable material for bone regeneration and novel strategies for fracture repair.

Qiang Pan-Hammarström

Clinical and genetic studies on malignant B cell lymphomas – basis for development of better prognostic models and novel therapies.

CIMED project grant 2022-2024 - Junior

Marco Gerling

A clinical tool for improved pancreatic cancer therapy and a molecular map of tumor invasion.

Published: 2021-06-23 08:36 | Updated: 2021-06-23 08:47

SEK 9.8 million from the Swedish Brain Foundation to MBB

The Department of medical biochemistry and biophysics (MBB) receives research grants of SEK 9.8 million from the Swedish Brain Foundation. Five projects at the department receive grants from the non-profit foundation.

Karolinska Institutet is awarded 42% out of the SEK 106 million included in this year’s allotment. Out of 38 at KI, 5 are located at MBB:

  • Ulrika Marklund is awarded SEK 1.6 million for the project ”Defining enteric neuronal circuits and their integration with the gut-brain axis”.
  • Nils-Göran Larsson is awarded SEK 1.2 million for the project ”Functional studies of CHCHD2, a new gene that causes Parkinson's disease”. Co-applicant is Roberta Filograna.
  • Ulf Eriksson is awarded SEK 1.6 million for the project ”Development of stroke and Alzheimer's Disease in diabetes”. Co-applicants are Ingrid Nilsson and Linda Fredriksson.
  • Jens Hjerling-Leffler is awarded SEK 3 million for the project ”Dissection of polygenic risk for Schizophrenia: genetics to experiments”.
  • Per Uhlén is awarded SEK 2.4 million for the project “3D Imaging of Cell Signaling in Traumatic Spinal Cord Injury”.

About Hjärnfonden

The Swedish Brain Foundation (Hjärnfonden) raises money for research and information about the brain and its diseases, injuries and disabilities. The Swedish Brain Foundation awards scholarships and grants to researchers and research groups to enable or enhance important research. The Swedish Brain Foundation also works to increase knowledge among the general public through information, lectures and seminars. The Swedish Brain Foundation has no government grants and is therefore completely dependent on donations from individuals and enterprises. The Swedish Brain Foundation has a so-called 90-account, which means that the Swedish Fundraising Control (Svensk Insamlingskontroll) controls the activities.

Subscribe to Grant